

1614

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/921,479
	Filing Date	08/03/2001
	First Named Inventor	R. Preston Mason
	Group Art Unit	1614
	Examiner Name	JONES, Dwayne C.
Total Number of Pages in This Submission	Attorney Docket Number	12915-1P06

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Post Card
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Stephen J. Gaudet Reg. No.: 48,921
Signature	
Date	2.27.04

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: February 27, 2004			
Typed or printed name	Renee P. Granito		
Signature		Date	2.27.04

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant:	Mason, P.)	
)	
Serial No.:	09/921,479)	
)	
Filed:	August 3, 2001)	Art Unit: 1614
)	Examiner: Jones, D. C.
Title:	Synergistic Effect of ...)	
)	
Docket No.:	12915-P06)	
)	
)	
)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING (37.C.F.R. 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MAIL STOP NON-FEE AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date set forth below.

2/27/04
date of mail deposit

By: 
Stephen J. Gaudet

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In reply to the Restriction Requirement dated February 2, 2004, Applicant files the following response.

Restriction Requirement

The Examiner has restricted the present application into four groups of claims. According to the Examiner, Group I is directed to a method of inhibiting cholesterol crystal formation and includes claims 39-49 and 93; Group II is directed to a method of increasing NO production and includes claims 50-60, 86-92, and 94-97; Group III is directed to a method treating arterial and related heart disease and includes claims 61-70; and Group IV is directed to a method of lowering blood pressure and systemic lipid concentrations and includes claims 72-83.

Applicant elects with traverse Group II, claims 50-60, 86-92, and 94-97 which are directed to a method for increasing NO production.

Applicant asserts that Groups I, II, III, and IV are not distinct inventions and should not be restricted. These groups are related, for example, Groups I, III, and IV are all related through Group IV. Group IV provides the fundamental basis for the practice of the claims recited in the other groups.


The underlying principle for the practice of Groups I, III, and IV claims certainly lies with Group II. Therefore, Applicant elects (with traverse) Group II for further prosecution. It is Applicant's intent that once Group II is allowed, that the other groups will be allowed upon amendment.

Therefore, claims 39-49, 93, 61-70, and 72-83 are withdrawn without prejudice at this stage of prosecution.

Although no fees are required, please charge any underpayment of fees to or credit any overpayment of fees to Deposit Account No. 50-1078.

The Examiner is invited to call the undersigned attorney at (617) 854-4237 should he determine that a telephonic interview would expedite prosecution of this case.

Respectfully submitted,



Stephen J. Gaudet, Ph.D.
Attorney for Applicant

Date: 2/27/01